Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study to Evaluate Disease Characteristics in Hemophilia B Participants Receiving Prophylaxis With Standard of Care FIX Replacement Therapy

NCT05568459 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT05568459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05568459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study to Evaluate Disease Characteristics in Hemophilia B Participants Receiving Prophylaxis With Standard of Care FIX Replacement Therapy
Lead sponsor
Regeneron Pharmaceuticals
Phase
Observational
Overall status
Active, not recruiting
Start date
January 17, 2024
Completion date
August 21, 2026
Enrollment
11 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b